Nazione: Australia
Lingua: inglese
Fonte: Department of Health (Therapeutic Goods Administration)
Dabigatran etexilate mesilate
Boehringer Ingelheim Pty Ltd
Medicine Registered
CMI0113-11 1 PRADAXA ® CAPSULES _Dabigatran _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Pradaxa. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking this medicine against the expected benefits. IF YOU HAVE ANY CONCERNS ABOUT USING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from your pharmacist, doctor or from www.medicines.org.au and may contain important information about the medicine and its use of which you should be aware. KEEP THIS INFORMATION WITH THE MEDICINE. You may need to read it again. WHAT PRADAXA IS USED FOR Pradaxa contains dabigatran etexilate (as dabigatran etexilate mesilate). After oral use, dabigatran etexilate is rapidly converted in the body to its active form dabigatran. Dabigatran inhibits a specific protein in the blood, called thrombin. Thrombin contributes to the formation of blood clots. Dabigatran prevents the formation of blood clots. This type of medication is called an anticoagulant. Some people refer to anticoagulant medicines as "blood thinners". Excessive clotting sometimes occurs when physical mobility is low such as following major orthopaedic surgery of the lower limb and due to a heart condition called atrial fibrillation in which the heart beats irregularly. If excessive clotting is not prevented, it can lead to serious health problems such as strokes. BEFORE YOU TAKE PRADAXA _WHEN Leggi il documento completo
PI0122-14 1 11 June 2013 PRADAXA (DABIGATRAN ETEXILATE) NAME OF THE MEDICINE Dabigatran etexilate mesilate is Ethyl N-{[2-({[4-((E)-amino{[hexyloxy)carbonyl]imino}methyl) phenyl]amino}methyl)-1-methyl-1H-benzimidazol-5-yl]carbonyl}-N-pyridin-2-yl- β-alaninate methanesulfonate. Molecular Formula: C 35 H 45 N 7 O 8 S Molecular Weight: 627.75 (free base) 723.86 (mesilate salt) CAS Registry Number: 211915-06-9 (free base) 593282-20-3 (mesilate) DESCRIPTION Dabigatran etexilate mesilate is a yellow-white to yellow crystalline powder; the crystals have a rod-like habit. It contains two weak basic centers with pKa-values of 4.0 ± 0.1 (benzimidazol moiety) and 6.7 ± 0.1 (carbamic acid hexyl ester moiety). Its solubility in water is strongly pH dependent with rather high solubility in acidic media (>50 mg/mL in 0.1 N HCl) and very poor solubility in neutral and basic media (0.003 mg/mL at pH 7.4). The solubility in water is 1.8 mg/mL (0.18%). In its neutral form it is very lipophilic (log P = 3.8, determined in different mixtures of aqueous solution and n-octanol). 75 mg hard capsules. Imprinted hypromellose capsules with light blue, opaque cap and cream- coloured, opaque body of size 2 filled with yellowish pellets. The cap is imprinted with the Boehringer Ingelheim company symbol, the body with R75. 110 mg hard capsules. Imprinted hypromellose capsules with light blue, opaque cap and cream- coloured, opaque body of size 1 filled with yellowish pellets. The cap is imprinted with the Boehringer Ingelheim company symbol, the body Leggi il documento completo